Market Overview

Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System

Share:
Related CERS
Friday's Zika Reports Explained: Winners And Losers
Watch These 10 Huge Call Purchases In Friday Trade

Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually.

Posted-In: News

 

Related Articles (CERS)

View Comments and Join the Discussion!